DE69936381D1 - Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie - Google Patents

Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie

Info

Publication number
DE69936381D1
DE69936381D1 DE69936381T DE69936381T DE69936381D1 DE 69936381 D1 DE69936381 D1 DE 69936381D1 DE 69936381 T DE69936381 T DE 69936381T DE 69936381 T DE69936381 T DE 69936381T DE 69936381 D1 DE69936381 D1 DE 69936381D1
Authority
DE
Germany
Prior art keywords
diabetic retinopathy
treatment
geniste
protein kinase
prophylactic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69936381T
Other languages
English (en)
Other versions
DE69936381T2 (de
Inventor
Juan Jr Eugene De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
School of Medicine of Johns Hopkins University
Original Assignee
Johns Hopkins University
School of Medicine of Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/042,440 external-priority patent/US5980929A/en
Priority claimed from US09041931 external-priority patent/US5919813C1/en
Application filed by Johns Hopkins University, School of Medicine of Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of DE69936381D1 publication Critical patent/DE69936381D1/de
Publication of DE69936381T2 publication Critical patent/DE69936381T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69936381T 1998-03-13 1999-03-12 Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie Expired - Lifetime DE69936381T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42440 1979-05-25
US09/042,440 US5980929A (en) 1998-03-13 1998-03-13 Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation
US41931 1998-03-13
US09041931 US5919813C1 (en) 1998-03-13 1998-03-13 Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
PCT/US1999/005477 WO1999045920A2 (en) 1998-03-13 1999-03-12 The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation

Publications (2)

Publication Number Publication Date
DE69936381D1 true DE69936381D1 (de) 2007-08-09
DE69936381T2 DE69936381T2 (de) 2007-10-31

Family

ID=26718704

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69936381T Expired - Lifetime DE69936381T2 (de) 1998-03-13 1999-03-12 Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie

Country Status (7)

Country Link
EP (2) EP1061913B1 (de)
JP (2) JP2002506028A (de)
AT (1) ATE365550T1 (de)
AU (1) AU756515B2 (de)
CA (1) CA2321560C (de)
DE (1) DE69936381T2 (de)
WO (1) WO1999045920A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100698449B1 (ko) * 1998-11-23 2007-03-23 노파르티스 아게 안구 혈관신생 질환 치료용 스타우로스포린 유도체의 용도
US6399107B1 (en) 1998-12-22 2002-06-04 Alcon Laboratories, Inc. Use of inhibitors of gag synthesis for the treatment of corneal haze
US6670321B1 (en) 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
JP4920134B2 (ja) * 1999-05-07 2012-04-18 ジョンズ ホプキンス ユニヴァーシティ スクール オヴ メディシン 眼障害の処置におけるプロテインチロシンキナーゼ経路インヒビターの使用
PT1221918E (pt) 1999-10-21 2005-06-30 Alcon Inc Administracao de drogas sub-tenon
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
CN1292721C (zh) 1999-10-21 2007-01-03 爱尔康公司 药物释放装置
US7943162B2 (en) 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
JP2003530309A (ja) * 1999-10-26 2003-10-14 イミューソル インコーポレイテッド 増殖性皮膚疾患又は増殖性眼疾患を治療するリボザイム療法
WO2003009784A1 (en) 2001-07-23 2003-02-06 Alcon, Inc. Ophthalmic drug delivery device
CN1203814C (zh) 2001-07-23 2005-06-01 爱尔康公司 眼部药物输送装置
WO2003047559A1 (en) * 2001-12-05 2003-06-12 Mitokor, Inc. Use of polycyclic phenolic compounds for the treatment of opthalmic diseases
GB0302882D0 (en) * 2003-02-07 2003-03-12 Univ Cardiff Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss
EP3168227B1 (de) 2003-05-02 2019-05-22 Centre National De La Recherche Scientifique Glut-1 als rezeptor für htlv-hüllen und dessen verwendungen
US9777044B2 (en) 2003-05-02 2017-10-03 Centre National De La Recherche Scientifique (Cnrs) GLUT-1 as a receptor for HTLV envelopes and its uses
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050261197A1 (en) * 2004-05-19 2005-11-24 Henry Aoki Coffee bean extract, method of extraction and composition containing the same
DK1848431T3 (en) 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
JP5528708B2 (ja) 2006-02-09 2014-06-25 参天製薬株式会社 安定な製剤ならびにそれらを調製および使用する方法
CN101443004B (zh) 2006-03-23 2013-03-06 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂
US20080181972A1 (en) * 2007-01-29 2008-07-31 Valentina Amico Compositions and Methods for Maintaining, Strengthening, Improving, or Promoting Eye Health
US9482677B2 (en) 2008-02-27 2016-11-01 Scios Inc. Method, composition and device for sampling natriuretic peptides in a biological fluid
EP2376917B1 (de) 2009-01-09 2016-03-30 Centre National De La Recherche Scientifique Neue rezeptorbindende liganden und ihre verwendung für den nachweis von zellen von biologischem interesse
US8632511B2 (en) 2009-05-06 2014-01-21 Alcon Research, Ltd. Multiple thermal sensors in a multiple processor environment for temperature control in a drug delivery device
US8177747B2 (en) 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
JP2015509500A (ja) * 2012-02-22 2015-03-30 ステルス ペプチドズ インターナショナル インコーポレイテッド 眼疾患を予防または治療するための方法および組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2078214C (en) * 1990-04-02 1995-03-28 Robert Lee Dow Benzylphosphonic acid tyrosine kinase inhibitors
WO1994003427A1 (en) * 1992-08-06 1994-02-17 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5710173A (en) * 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
US5834513A (en) * 1996-04-25 1998-11-10 Avon Products, Inc. Oxa diacids and related compounds for treating skin conditions

Also Published As

Publication number Publication date
DE69936381T2 (de) 2007-10-31
EP1061913B1 (de) 2007-06-27
EP1061913A2 (de) 2000-12-27
EP1806135A2 (de) 2007-07-11
CA2321560A1 (en) 1999-09-16
ATE365550T1 (de) 2007-07-15
CA2321560C (en) 2007-05-22
WO1999045920A2 (en) 1999-09-16
JP2010168389A (ja) 2010-08-05
JP2002506028A (ja) 2002-02-26
AU756515B2 (en) 2003-01-16
AU3001999A (en) 1999-09-27
EP1806135A3 (de) 2010-11-24
WO1999045920A3 (en) 1999-10-21

Similar Documents

Publication Publication Date Title
DE69936381D1 (de) Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie
FR18C1012I2 (fr) Derives de staurosporine inhibiteurs de l'activite tyrosine kinase du recepteur flt3
ES2152556T3 (es) Composiciones que contienen derivados del acido hidroperoxieicosatetraenoico y procedimientos de utilizacion en el tratamiento de trastornos de la sequedad ocular.
EA200200990A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы дельта человека
WO1998010767A3 (en) Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
DE69521620T2 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
DE60027431D1 (de) Verwendung von p38 MAPK Inhibitoren in der Behandlung von Augenkrankheiten
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE60028740D1 (de) Phthalazinderivate zur behandlung von entzündlicher erkrankungen
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
DE60031396D1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
ATE381935T1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
SE9803710D0 (sv) Use of certain drugs for treating nerve root injury
BR0213738A (pt) proteìnas morfogênicas ósseas (bmp), receptores de bmp e proteìnas de ligação de bmp e seu uso no diagnóstico e no tratamento de glaucoma
PT950057E (pt) Enantiomeros de 3-piridilo e sua utilizacao como analgesicos
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
DE69814394D1 (de) Verwendung von levobupivacain
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
EE200100188A (et) Optiliselt aktiivne püridüül-4H-1,2,4-oksadiasiini derivaat ja selle kasutamine vaskulaarsete haiguste ravis
DE69912304D1 (de) Verwendung von staurosporine derivaten zur behandlung von okularen neovaskularen erkrankungen
ATE359774T1 (de) Taurinderivate verwendbar in der behandlung von netzhauterkrankungen
MXPA01011344A (es) El uso de un inhibidor de la ruta de proteina tirosina quinasa en el tratamiento de trastornos oculares.
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
ES2098030T3 (es) Nuevos agentes cardioprotectores.
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk

Legal Events

Date Code Title Description
8364 No opposition during term of opposition